GTx reports results for enobosarm POWER trials for the prevention and treatment of muscle wasting in patients with NSCLC

GTx, Inc. (Nasdaq: GTXI) has announced results of its two Phase 3 enobosarm clinical trials, the POWER trials, in patients with non-small cell lung cancer receiving chemotherapy. The Company announced that the clinical trials failed to meet the overall criteria for the co-primary responder endpoints of lean body mass and physical function as agreed upon with the United States Food and Drug Administration; the responder endpoints showed mixed results (for POWER1 and POWER2, p values at Day 84 for LBM were 0.036 and 0.113, respectively; p values at Day 84 for SCP were 0.315 and 0.289, respectively). Read more here.